Efficacy of combination antiretroviral therapy

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 355-372

  Collier, Ann C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATEVIRDINE; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOVIRIDE; MIGLUSTAT; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SC 49483; STAVUDINE; TRICHOSANTHIN; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHOCYTE COUNT; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029877185     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_33     Document Type: Conference Paper

References (100)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-191.
2. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. JAMA 1988;260:3009-3015.
3. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-1416.
4. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992;267:1232-1236.
5. Volberding P, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-949.
6. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112:727-737.
7. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
8. Moore RD, Keruly J, Richman DD, et al. Natural history of advanced HIV disease in patients treated with zidovudine. AIDS 1992;6:671-677.
9. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP, for the National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the art conference. JAMA 1993;270:2583-9.
10. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-587.
11. Spruance S, Pavia A, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine: a randomized, double-blind clinical trial. Ann Intern Med 1994;120:360-368.
12. Pavia AT, Gathe J, BMS-019 Study Group Investigators, et al. Clinical efficacy of stavudine (d4T, Zerit) in ZDV-pretreated HIV-positive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995. Session 86. Abstract I169.
13. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses 1994;10:907-12.
14. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.
15. Kong XB, Zhu QY, Ruprecht RM, et al. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′ -deoxythymidine, phosphonoformate, and 2′, 3′ -dideoxythymidine. Antimicrob Agents Chemother 1991;35:2003-11.
16. Johnson VA, Barlow MA, Merrill DB, Chou T-C, Hirsch MS. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 1990;161:1059-67.
17. Sorensen AM, Nielsen C, Mathiesen LR, Nielsen JO, Hansen JE. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scan J Infect Dis 1993;25:365-71.
18. Rusconi S, Merrill DP, Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 1994;170:1361-6.
19. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidme, or recombinant interferon-αA against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis. 1992;166:1143-6.
20. Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS 1993;7:1181-4.
21. Pagano PJ, Chong K-T. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α. J Infect Dis 1995;171:61-7.
22. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989;243:1731-1734.
23. Larder BA, Kemp SD, Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine. Science 1989;246:1155-1159.
24. Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxy-ucleosides. Journal of Exp Med 1988;168:1111-25.
25. Perno CF, Yarchoan R, Balzarini J, et al. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res 1992; 17:289-304.
26. Gao W-Y, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
27. Chow Y-K, Hirsch MS, Merrill DP, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993;361:650-4.
28. Chow Y-K, Hirsch MS, Kaplan JC, D'Aquilla RT HIV-1 error revealed (letter to editor) Nature 1993;364:679.
29. Emini EA, Graham DJ, Gotlib L, Condra JH, Byrnes VW, Schleif WA. HIV and multidrug resistance (letter to editor). Nature 1993;364:679.
30. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared to zidovudine alone in HTV-1 infection. Ann Intern Med, 1993;119:786-793.
31. Ragni MV, Amato DA, LoFaro ML, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. Blood 1995;85:2337-46.
32. Yarchoan R, Lietzau JA, Nguyen B-Y, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9-17.
33. Schooley RC. Combined Antiretroviral Therapy Meeting, Lisbon, Portugal, July 1995.
34. Kojima E, Shirasaka T, Anderson, BD, et al. Human immunodeficiency virus type 1 (HIV)-1 viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995;171:1152-8.
35. 3. 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995, Session 33. LB-1.
36. Katzenstein D, Hammer S, Hughes H, et al, for the ACTG 175 Virology Team. Plasma virion RNA in response to early antiretroviral drug therapy in ACTG 175: do changes in virus load parallel clinical and immunologic outcomes? 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995, Session 33. LB-2.
37. Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13-20.
38. Fischl, MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24-32.
39. Richman DD, Grimes JM, and Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990;3:743-746.
40. Edlin BR, St. Clair MH, Pitha PM, et al. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med 1992;117:457-460
41. Land S, Treloar G, McPhee D, et al. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 1990;161:326-329.
42. Wainberg MA, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995;9:351-7.
43. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3°-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
44. Kuritzkes DR, Bell S, Shugarts D, et al. Development of resistance to lamivudine (3TC) in NUCA 3001, a Phase II comparative trial of 3TC vs zidovudine (ZDV) vs 3TC plus ZDV. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB36.
45. Larder BA, Kemp SD, Harrigan PR, Kinghorn I, Kohli A, Bloor S. Antiviral potency of AZT + 3TC combination therapy supports virological observations. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB33.
46. 3. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB34.
47. 3. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB31.
48. 3. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB32.
49. 3. 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29-February 2, 1995, Abstract LB35.
50. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697-661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72.
51. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
52. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;8:141-51.
53. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
54. Freimuth WW, Davey R, Batts R, et al. Phase II clinical trials of delavirdine mesylate combination therapy. 10th International Conference on AIDS, Yokohama, Japan, August 7-12, 1994, Abstract #512B.
55. Staszewski S, Massari FE, Kober A, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995;171:1159-65.
56. Reichman RC, Morse GD, Demeter LM, et al. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:297-304.
57. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
58. Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone (BI-RG-587). J Infect Dis 1991;163:966-70.
59. Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergizes with zidovudine. Antimicrob Agents Chemother 1991;35:305-8.
60. AIDS Clinical Trial Group (ACTG) 241 Protocol Team ACTG 241: Executive Summary. November 16, 1994.
61. Dueweke TJ, Poppe SM, Romero DL, et al. U-90152S, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993;37:1126-31.
62. 1 patients 10th International Conference on AIDS. Yokohama, Japan, August 7-12, 1994, Abstract #513B.
63. Kramer RA, Schaber MD, Skalka AM, Ganguly K, Wong-Staal F, Reddy EP HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986;231:1580-4.
64. Lambert DM, Petteway SR Jr, McDanal CE, et al. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992:36:982-8.
65. Ashorn P, McQuade TJ, Thasrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA 1990;87:7472-6.
66. McQuade TJ, Tomasselli AG, Liu L, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrest HIV-like particle maturation. Science 1990;247:454-6
67. Craig JC, Whittaker C, Duncan IB, Roberts NA In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antiviral Chem Chemother 1994;5:380-386.
68. Craig JC, Duncan IB, Whittaker L, Roberts NA. Antiviral synergy between inhibitors of HIV protease and reverse transcriptase. Antiviral Chem Chemother 1992;4:161-166.
69. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
70. Coudra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
71. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Research Report W-141'452. Antiviral Res. 1991;16:295-305.
72. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345:952-5.
73. Vella S. HIV therapy advances. Update on a proteinase inhibitor. AIDS 1994; 8:S25-9.
74. Collier AC, Coombs RC, Schoenfeld DA, et al. Extended treatment with saquinavir (SAQ), zidovudine (ZDV), and zalcitabine (ddC) vs SAQ and ZDV versus ddC and ZDV. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995. Session 86. Abstract 1173.
75. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206:527-34.
76. Dorsey BD, Levin RB, McDaniel SL, et al. L-735,425: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994;37:3443-51.
77. 3. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995. Session 86. Abstract I172.
78. Massari F, Staszewski S, Berry P, et al. Double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine versus zidovudine alone in zidovudine naive patients. 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995, Session 33. LB-6.
79. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-8.
80. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
81. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995, Session 33. LB-7.
82. Lane HC, Kovacs JA, Feinberg J, et al. Antiretroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2:1218-22.
83. de Wit R, Schattenkerk JK, Boucher CA, et al. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988; 2:1214-7.
84. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-a with zidovudine: safety, tolerance and clinical virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112:812-21.
85. Mildvan D, Bassiakosy D and the ACTG 068 Collaborative Group. Zidovudine and interferon-α2A: ongoing assessment of synergy and tolerance in early ARC patients, ACTG 068. Abstract PoB 3586. Eighth International Conference on AIDS. July 19-24, 1992, Amsterdam, Netherlands.
86. Edlin BR, Weinstein RA, Whaling SM, et al. Zidovudine-interferon-α combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. J Infect Dis 1992;165:793-8.
87. Frissen PHJ, van der Ende ME, Napel CHHT, et al. Zidovudine and interferon-α combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:1351-5.
88. deBoer JB, van Dam FS, Sprangers MA, Frissen PH, Lange JM. Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha. AIDS 1993;7:947-53.
89. 3-results of the "zidon" trial. 10th International Conference on AIDS, Yokohama, Japan, August 7-12, 1994, Abstract #059B.
90. Karpas A, Fleet GW, Dwek R, et al. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA 1988;85:9229-33.
91. Ratner L, Vander Heyden N, Dedera D. Inhibition of HIV and SIV infectivity by blockade of α-glucosidase activity. Virology 1991;181:180-92.
92. 3. Journal of Acquired Immune Deficiency Syndromes 1994;7:139-147.
93. Maraganore JM, Bailey JM. Purification and characterization of trichosanthin. Homology to the ricin A chain and implications as to mechanism of abortifacient activity. J Biol Chem 1987;262:11628-33.
94. McGrath MS, Hwang KM, Caldwell SE, et al. GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci USA 1989;86:2844-8.
95. Kahn J, Gorelik K. Results of a randomized study of GLQ223 in AIDS and ARC. 10th International Conference on AIDS, Yokohama, Japan, August 7-12, 1994, Abstract #006B.
96. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;26:6801-5.
97. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′, 3′ -dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1991;91:11017-21.
98. Gao W-Y, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′, 3′ -dideoxynucleosides Mol Pharm 1994;46:767-72
99. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 1994;343:1292.
100. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10:36-40.